Skip to main content

Eric Warren

Analyst

Sales Team Representative

Equibles does not estimate personal net worth.

About Eric Warren

Eric Warren is recorded as Analyst at Sales Team Representative. The proxy statement of Esperion Therapeutics, Inc. reports total compensation of $1,149,844 for Eric Warren in fiscal 2024, including a base salary of $481,867. Disclosed compensation is on record for 2 fiscal years. Eric Warren has spoken on 4 earnings calls and 1 other investor event across 1 company, most recently for Mineralys Therapeutics, Inc. on September 9, 2026. Mineralys Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Mineralys Therapeutics, Inc. includes Jon Congleton (CEO and Board Member), Glenn P. Sblendorio (Chairman), Alexander Gold (Board Member) and 7 others.

Eric Warren on recent calls

“Yeah, so gaining experience in fourth line is a natural kind of predictor of increased third line utilization. Guidelines very well could play a role in that as well.”
Other, Wells Fargo 21st Annual Healthcare Conference ·
“Approximately 20 million adults in the United States have uncontrolled or resistant hypertension, and despite the availability of numerous antihypertensive therapies, these patients remain unable to achieve their blood pressure goal.”
Other, Second Quarter 2026 Earnings Call ·
“So it's all about sequencing, Richard, so that fourth line is the entry point. But obviously, there is a need for those comorbid patients that are third-line patients.”
Other, Mineralys Therapeutics, Inc. Q1 FY2026 Earnings Call ·
“Yeah, and Jason, I'm just back from a large payer conference in Orlando, PCMA, where the team was engaging Medicare as well as commercial payers. I will say we're on their radar.”
Mineralys Therapeutics, Inc. Q4 FY2025 Earnings Call ·
“I'll just add that the definition of goal was different when looking at the Bax24 data, where they used a more lenient definition. We used a more stringent definition.”
CCO, Mineralys Therapeutics, Inc. Q3 FY2025 Earnings Call ·

Affiliation history

  • Sales Team Representative

    Analyst

    Source not stated

    Current
  • Current
  • Esperion Therapeutics, Inc.

    Proxy statement

    Start not stated–2025-04-18

Company network

Esperion Therapeutics, Inc.

Drug Manufacturers - Specialty & Generic · Healthcare

Leadership on record at Mineralys Therapeutics, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2024 Esperion Therapeutics, Inc. $481,867 $1,149,844
2023 Esperion Therapeutics, Inc. $462,500 $1,077,705

Recent activity